San Diego-based drug maker Orexigen Therapeutics Inc. on Wednesday got a green signal from the Food and Drug Administration (FDA) for its new pill to treat overweight and obesity problem.
The new weight-loss drug, Contrave, will be marketed by Takeda Pharmaceutical of Japan.
This is the third time in about two years when the federal health body has approved any weight-loss medication. Recently, two new pills, Qsymia and Belviq, had got FDA nod as ideal options to help adults fight their flab.
Contrave is a combination of two drugs: naltrexone and bupropion.
While Naltrexone is used to treat over dependence on alcohol and drug, bupropion is an antidepressant used to treat mood disorder and also as a smoking cessation treatment.
Contrave, alike its rivals, is effective in treating people who are obese or overweight and also the weight-related health issues like diabetes.
The FDA recommends intake of these medicines under proper guidance as they carry some side effects and drawbacks too. According to the reports, all the new medications for weigh loss work by decreasing your appetite, hence, none of the three new drugs promise massive weight loss.
“Obesity continues to be a major public health concern. When used as directed in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, Contrave provides another treatment option,” the Jean-Marc Guettier from FDA said in a press release.
The FDA has also warned that the drug may increase suicidal thoughts among the people who use it. Some of the other possible side effects of the drug include rise in blood pressure and heart rate, the FDA said.
As some of the obesity drugs in the past have been associated with serious heart-related problems, leading to their ouster from the market, the FDA has asked the makers of all the three newly approved medications- Contrave, Qsymia and Belviq- to conduct a long-term studies related to heart safety and submit a report to the federal body.